2024. Comparative Study of Olopatadine Hydrochloride 0.1% and Emedastine difumarate 0.05% Comparing their Clinical Efficacy and Adverse Effects in Allergic Conjunctivitis. Medical Forum Monthly. 26, 5 (May 2024).